Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fluzoparib Maintenance in gBRCA/PALB2 Mutated Metastatic Pancreatic Cancer
NCT04300114Phase 3Terminated
- Sponsor
- Hengrui
- Start
- Aug 2020
- Primary completion
- Feb 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in pancreatic cancer (PC) comparing Maintenance Fluzoparib monotherapy with Maintenance placebo monotherapy (2 arms). Primary endpoint: Progression-Free Survival up to 3 years. Started Aug 2020; status: terminated.
02
Drugs
fluzoparib
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on NCT04300114.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04300114.